Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis
详细信息 查看全文
- 作者：Ilaria Cegliaa ; Amylou C. Dueckb ; Francesca Masielloc ; Fabrizio Martellic ; Wu Hed ; Giulia Federicic ; e ; Emanuel F. Petricoin IIIf ; Ann Zeunerc ; Camelia Iancu-Rubina ; Rona Weinbergg ; Ronald Hoffmana ; John Mascarenhasa ; Anna Rita Migliaccioa ; h ; annarita.migliaccio@mssm.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Experimental Hematology
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：44
- 期：12
- 页码：1138-1155.e4
- 全文大小：6893 K
文摘
- •
TGF-β inhibition has no effect on the proliferation of CD34+ cells and Erys from PMF.
- •
In contrast, TGF-β inhibition increases proliferation of CD34+ cells and Erys from AB.
- •
TGF-β inhibition increases proliferation of CD34+ cells, but not of Erys, from CB.
- •
TGF-β inhibition increases proliferation of Erys, but not of CD34+ cells, from PV.
- •
Therefore, TGF-β inhibition may reactivate normal over malignant hematopoiesis in PMF.